All the data suggest LMF-HSFx may reduce the insulin resistance in NAFLD patients through the regulation of Adiponectin-AdipoR1/2 pathways [36], which contribute the critical part of insulin resistance. This evidence concerns the gene ADIPOR1 and metabolic dysfunction-associated steatotic liver disease.